Lys413
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys413  -  LEO1 (human)

Site Information
EEGRTRLkLkVENTI   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12252300

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Relevant cell line - cell type - tissue:
293T (epithelial) ( 1 ) , LNCaP (prostate cell) ( 2 , 3 , 4 ) , MV4-11 (macrophage) ( 1 )

References 

1

Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284
21890473   Curated Info

2

Possemato A (2009) CST Curation Set: 8244; Year: 2010; Biosample/Treatment: cell line, LNCaP/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

3

Possemato A (2009) CST Curation Set: 8246; Year: 2010; Biosample/Treatment: cell line, LNCaP/Velcade; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

4

Possemato A (2009) CST Curation Set: 8245; Year: 2010; Biosample/Treatment: cell line, LNCaP/Geldanamycin; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info